Form 4: Cumberland Pharmaceuticals Director Acquires 5,000 Shares of Common Stock
SEC Form 4
Kenneth Krogulski, a director of Cumberland Pharmaceuticals, acquired 5,000 shares of common stock at a price of $1.71 per share on March 25, 2024.
Summary
- On March 25, 2024, Kenneth Krogulski, a director of Cumberland Pharmaceuticals, acquired 5,000 shares of common stock.
- The purchase price was $1.71 per share.
- Following the transaction, Krogulski directly owns 241,277 shares of Cumberland Pharmaceuticals.
- The acquisition was a restricted stock award that will vest 100% on March 25, 2025.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It reflects a routine transaction by a company director. The purchase could be seen as a positive signal, but it's not a major event.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This transaction is a routine disclosure of insider trading activity. It provides insight into the actions of company directors, which can be informative for investors.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of stock acquisition by Kenneth Krogulski |
| 03/25/2025 | Vesting date of the restricted stock award |
| 03/26/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.